Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-02665 |
Aldolase C Protein, Mouse, Recombinant (His & Myc)
Aldolase 3,Brain-type aldolase,Aldo3,S... |
Mouse | E. coli |
Aldolase C Protein, Mouse, Recombinant (His & Myc) is expressed in E. coli with N-terminal 10xHis tag and C-terminal Myc tag. The predicted molecular weight is 46.7 kDa. Accession number: P05063 | |||
TMPH-02664 |
Aldolase C Protein, Mouse, Recombinant (His)
Aldo3,Brain-type aldolase,Zebrin II,Fructo... |
Mouse | P. pastoris (Yeast) |
Aldolase C Protein, Mouse, Recombinant (His) is expressed in Yeast. | |||
TMPJ-00818 |
ALDOC Protein, Human, Recombinant (His)
Aldolase C,ALDC,zebrin II,Aldo3,S... |
Human | HEK293 Cells |
Fructose-bisphosphate aldolase C (ALDOC) belongs to the class I fructose-bisphosphate aldolase family. It is an enzyme that, in humans, is encoded by the ALDOC gene. ALDOC is expressed exclusively in the hippocampus and Purkinje cells of the brain. ALDOC is a glycolytic enzyme which catalyzes the reversible aldol cleavage of fructose-1,6-biphosphate and fructose 1-phosphate to dihydroxyacetone phosphate and either glyceraldehyde-3-phosphate or glyceraldehydes respectively | |||
TMPH-02662 |
Aldolase A Protein, Mouse, Recombinant (His)
Aldolase 1,Fructose-bisphosphate aldol... |
Mouse | Baculovirus Insect Cells |
Plays a key role in glycolysis and gluconeogenesis. In addition, may also function as scaffolding protein. Aldolase A Protein, Mouse, Recombinant (His) is expressed in Baculovirus insect cells with C-6xHis tag. The predicted molecular weight is 40.3 kDa and the accession number is P05064. | |||
TMPH-02663 |
Aldolase A Protein, Mouse, Recombinant (His & Myc)
Aldoa,Aldolase 1,Fructose-bisphosphate |
Mouse | E. coli |
Plays a key role in glycolysis and gluconeogenesis. In addition, may also function as scaffolding protein. Aldolase A Protein, Mouse, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 46.7 kDa and the accession number is P05064. | |||
TMPJ-01411 |
HSPB11 Protein, Human, Recombinant (His)
PP25,Placental Protein 25,Heat Shock Prote... |
Human | E. coli |
Heat Shock Protein β-11 (HSPB11) is a stress-responsive protein that is required to deal with proteotoxic stresses. HSPB11 is composed of an IFT complex B composed of IFT88, IFT57, TRAF3IP1, IFT52, IFT27, HSPB11 and IFT20 and is detected in placenta. HSPB11 has beeb shown to form oligomeric complexes and prevent the aggregation of in vitro denaturated aldolase and glyceraldehyde-3-phosphate dehydrogenase in accordance with the chaperone model of HSPB1 and HSPB5. HSPB11 overexpression protected a... | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |